Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Zloza

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Journal for Immunotherapy of Cancer|September 20, 2017
Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancerAndrew Zloza, A Karolina Palucka, Lisa M Coussens, et al.
European Journal of Medical Research|July 2, 2022
A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumorsAnn W Silk, Biren Saraiya, Roman Groisberg, et al.
Frontiers in Oncology|January 31, 2020
High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced MelanomaAnn W Silk, Howard L Kaufman, Brendan Curti, et al.
Pigment Cell & Melanoma Research|February 18, 2018
A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanomaJanice M Mehnert, Ann W Silk, J H Lee, et al.
Diagnostics (Basel, Switzerland)|April 23, 2022
Gut Microbial Shifts Indicate Melanoma Presence and Bacterial Interactions in a Murine ModelMarco Rossi, Salvatore M Aspromonte, Frederick J Kohlhapp, et al.
JID Innovations : Skin Science From Molecules to Population Health|March 6, 2024
Assessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse ModelKevinn Eddy, Kajal Gupta, Mohamad Naser Eddin, et al.
AIDS Research and Human Retroviruses|March 6, 2014
HIV infection accelerates gastrointestinal tumor outgrowth in NSG-HuPBL miceRong Lu, Shaoping Wu, Yongguo Zhang, et al.
Elife|February 3, 2022
Overriding impaired FPR chemotaxis signaling in diabetic neutrophil stimulates infection control in murine diabetic woundRuchi Roy, Janet Zayas, Sunil K Singh, et al.
Nature Medicine|December 13, 2016
Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney diseaseEunsil Hahm, Changli Wei, Isabel Fernandez, et al.
The Journal of Clinical Investigation|March 14, 2018
Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitmentJessica Wagner, C Leah Kline, Lanlan Zhou, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Journal for Immunotherapy of Cancer|September 20, 2017
Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancerAndrew Zloza, A Karolina Palucka, Lisa M Coussens, et al.
European Journal of Medical Research|July 2, 2022
A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumorsAnn W Silk, Biren Saraiya, Roman Groisberg, et al.
Frontiers in Oncology|January 31, 2020
High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced MelanomaAnn W Silk, Howard L Kaufman, Brendan Curti, et al.
Pigment Cell & Melanoma Research|February 18, 2018
A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanomaJanice M Mehnert, Ann W Silk, J H Lee, et al.
Diagnostics (Basel, Switzerland)|April 23, 2022
Gut Microbial Shifts Indicate Melanoma Presence and Bacterial Interactions in a Murine ModelMarco Rossi, Salvatore M Aspromonte, Frederick J Kohlhapp, et al.
JID Innovations : Skin Science From Molecules to Population Health|March 6, 2024
Assessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse ModelKevinn Eddy, Kajal Gupta, Mohamad Naser Eddin, et al.
AIDS Research and Human Retroviruses|March 6, 2014
HIV infection accelerates gastrointestinal tumor outgrowth in NSG-HuPBL miceRong Lu, Shaoping Wu, Yongguo Zhang, et al.
Elife|February 3, 2022
Overriding impaired FPR chemotaxis signaling in diabetic neutrophil stimulates infection control in murine diabetic woundRuchi Roy, Janet Zayas, Sunil K Singh, et al.
Nature Medicine|December 13, 2016
Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney diseaseEunsil Hahm, Changli Wei, Isabel Fernandez, et al.
The Journal of Clinical Investigation|March 14, 2018
Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitmentJessica Wagner, C Leah Kline, Lanlan Zhou, et al.
Pageof 8